Literature DB >> 12855602

Role of Wilms tumor 1 (WT1) in the transcriptional regulation of the Mullerian-inhibiting substance promoter.

Anwar Hossain1, Grady F Saunders.   

Abstract

The Wilms tumor 1 (WT1) gene product may regulate the mullerian-inhibiting substance (MIS) gene, because mutations in WT1 can cause persistence of the mullerian duct in men. In the present study, we show by gel shift and chromatin immunoprecipitation assays that WT1 bound to a GC-rich sequence in the murine Mis promoter. Mutation in this site abolished WT1-mediated activation of the Mis promoter. The WT1, SRY box protein 9, and steroidogenic factor 1 could synergistically activate the Mis promoter, and at least two factors were necessary for minimal activation. The WT1 is an essential factor for activation of the Mis promoter; therefore, the persistence of the mullerian duct in patients with Denys-Drash syndrome may result from deregulation of the MIS gene.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12855602     DOI: 10.1095/biolreprod.103.015826

Source DB:  PubMed          Journal:  Biol Reprod        ISSN: 0006-3363            Impact factor:   4.285


  12 in total

Review 1.  Müllerian inhibiting substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers.

Authors:  David T MacLaughlin; Patricia K Donahoe
Journal:  Future Oncol       Date:  2010-03       Impact factor: 3.404

2.  Regulation of vascular endothelial growth factor, VEGF, gene promoter by the tumor suppressor, WT1.

Authors:  Julie Hanson; Jacquelyn Gorman; Jennifer Reese; Gail Fraizer
Journal:  Front Biosci       Date:  2007-01-01

Review 3.  Molecular genetics of Müllerian duct formation, regression and differentiation.

Authors:  Rachel D Mullen; Richard R Behringer
Journal:  Sex Dev       Date:  2014-07-12       Impact factor: 1.824

4.  SUMOylation inhibits SF-1 activity by reducing CDK7-mediated serine 203 phosphorylation.

Authors:  Wei-Hsiung Yang; Joanne H Heaton; Holly Brevig; Sarmistha Mukherjee; Jorge A Iñiguez-Lluhí; Gary D Hammer
Journal:  Mol Cell Biol       Date:  2008-11-17       Impact factor: 4.272

5.  Regulation of Wilms' tumor gene expression by nerve growth factor and follicle-stimulating hormone in the immature mouse ovary.

Authors:  Jaesook Roh; Jeehyeon Bae; Kangseok Lee; Kelly Mayo; Lonnie Shea; Teresa K Woodruff
Journal:  Fertil Steril       Date:  2008-09-06       Impact factor: 7.329

6.  Wilms' tumor protein Wt1 is an activator of the anti-Müllerian hormone receptor gene Amhr2.

Authors:  Jürgen Klattig; Ralph Sierig; Dagmar Kruspe; Birgit Besenbeck; Christoph Englert
Journal:  Mol Cell Biol       Date:  2007-04-09       Impact factor: 4.272

Review 7.  Mechanisms of transcriptional regulation by WT1 (Wilms' tumour 1).

Authors:  Eneda Toska; Stefan G E Roberts
Journal:  Biochem J       Date:  2014-07-01       Impact factor: 3.857

8.  A GATA4/WT1 cooperation regulates transcription of genes required for mammalian sex determination and differentiation.

Authors:  Yoko Miyamoto; Hiroaki Taniguchi; Frédéric Hamel; David W Silversides; Robert S Viger
Journal:  BMC Mol Biol       Date:  2008-04-29       Impact factor: 2.946

Review 9.  Müllerian inhibiting substance/anti-Müllerian hormone: A novel treatment for gynecologic tumors.

Authors:  Jang Heub Kim; David T MacLaughlin; Patricia K Donahoe
Journal:  Obstet Gynecol Sci       Date:  2014-09-17

10.  Disruption of genital ridge development causes aberrant primordial germ cell proliferation but does not affect their directional migration.

Authors:  Su-Ren Chen; Qiao-Song Zheng; Yang Zhang; Fei Gao; Yi-Xun Liu
Journal:  BMC Biol       Date:  2013-03-05       Impact factor: 7.431

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.